Tempus AI Secures Bristol-Myers Squibb–Anthropic AI Deal While Shares Slip 0.4%
Tempus AI shares slipped 0.4% to $35.46 following a 23.1% year-to-date decline, and short interest equal to 24.5% of float implies nearly five days to cover. The platform will be integrated into a Bristol-Myers Squibb–Anthropic AI initiative on oncology and neuroscience drug discovery.
1. Short Interest Trends and Stock Movement
Tempus AI shares dipped 0.4% to $35.46, extending a 23.1% year-to-date decline. Short interest represents 24.5% of available float, equating to nearly five days to cover at average trading volumes, underscoring potential volatility from bearish positioning.
2. Bristol-Myers Squibb–Anthropic AI Collaboration
Tempus’ analytical platform will be integrated into a new Bristol-Myers Squibb–Anthropic AI initiative targeting oncology and neuroscience drug discovery. The collaboration aims to leverage multimodal data and advanced machine learning to streamline research, clinical development and manufacturing, potentially driving product pipeline efficiency and revenue growth.